Eli Lilly plans to acquire Ajax Therapeutics for up to $2.3 billion to develop a potential new oral treatment for myelofibrosis, a rare blood cancer. The company expects key clinical data in 2026 and intends to rapidly advance the program into larger trials, aiming to add another targeted option for patients and specialists.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
